Inhalation Sciences Sweden AB (publ) (ISAB.ST)
Stockholm · SEK · Healthcare · Medical Devices
SEK 0.081 (+0.00%) as of
Key statistics
- Market cap
- 4.15M
- EPS (TTM)
- -0.2100
- Dividend yield
- 0.00%
- 52-week range
- 0.0470 – 0.6900
- Beta
- -0.08
- Revenue (TTM)
- 8.3M
- Profit margin
- -103.11%
- Volume
- 62.24k
About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research in Sweden. The company offers PreciseInhale, a laboratory system that allows scientists to measure how inhaled particles act in lungs and affect the health; DissolvIt, which enables in vitro simulation of dissolution and absorption of respirable particles in the lung epithelium; XposeALI, a 3D cell exposure module that combines aerosol capability with 3D cell models cultured at an air liquid interface; Nose-only inhalation, a standard method of exposure used in preclinical testing of inhalation drugs, as well as for inhalation toxicity studies in rodents; and intratracheal exposure module, an unique technology delivering aerosol directly to the lungs, bypassing the nose, and to spontaneously breathing rodents. Inhalation Sciences Sweden AB (publ) was incorporated in 2004 and is based in Huddinge, Sweden.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Huddinge, Sweden
- Employees
- 5
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.